Ritter Pharmaceuticals has announced a public offering of class A units to raise $10m.

The US-based pharmaceutical company plans to use the funds for general corporate purposes, including research and development (R&D) programmes and working capital.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

US-based Sienna Biopharmaceuticals plans to raise $74.75m through an initial public offering (IPO) of common stock shares.

Sienna plans to use the funds from the offering towards the development of SNA-120.

"US-based Sienna Biopharmaceuticals plans to raise $74.75m through an initial public offering (IPO) of common stock shares."

Exscientia has formed a strategic partnership with GlaxoSmithKline (GSK) to carry out drug programmes for the latter.

The artificial intelligence-based drug discovery company will undertake programmes aimed at discovering novel and selective small molecules for various targets identified by GSK.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Australian life science company BARD1 Life Sciences has announced two offerings of 137 million common stock shares and 125 million shares priced at A$0.008 ($0.006) a share, to raise a total of A$2m ($1.6m).

BARD1 plans to use the funds towards R&D programmes and for general corporate purposes.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now